|
1
|
Ito H and Matsuo K: Molecular
epidemiology, and possible real-world applications in breast
cancer. Breast Cancer. 23:33–38. 2016. View Article : Google Scholar
|
|
2
|
Khan MA, Jain VK, Rizwanullah M, Ahmad J
and Jain K: PI3K/AKT/mTOR pathway inhibitors in triple-negative
breast cancer: A review on drug discovery and future challenges.
Drug Discov Today. 24:2181–2191. 2019. View Article : Google Scholar
|
|
3
|
Ellsworth RE, Blackburn HL, Shriver CD,
Soon-Shiong P and Ellsworth DL: Molecular heterogeneity in breast
cancer: State of the science and implications for patient care.
Semin Cell Dev Biol. 64:65–72. 2017. View Article : Google Scholar
|
|
4
|
Harbeck N, Penault-Llorca F, Cortes J,
Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F:
Breast cancer. Nat Rev Dis Primers. 5:662019. View Article : Google Scholar
|
|
5
|
El Etreby MF, Liang Y, Wrenn RW and
Schoenlein PV: Additive effect of mifepristone and tamoxifen on
apoptotic pathways in MCF-7 human breast cancer cells. Breast
Cancer Res Treat. 51:149–168. 1998. View Article : Google Scholar
|
|
6
|
Arab A, Yazdian-Robati R and Behravan J:
HER2-Positive breast cancer immunotherapy: A focus on vaccine
development. Arch Immunol Ther Exp (Warsz). 68:22020. View Article : Google Scholar
|
|
7
|
Chacón RD and Costanzo MV: Triple-negative
breast cancer. Breast Cancer Res. 12 (Suppl 2):S32010. View Article : Google Scholar
|
|
8
|
Chang-Qing Y, Jie L, Shi-Qi Z, Kun Z,
Zi-Qian G, Ran X, Hui-Meng L, Ren-Bin Z, Gang Z, Da-Chuan Y and
Chen-Yan Z: Recent treatment progress of triple negative breast
cancer. Prog Biophys Mol Biol. 151:40–53. 2020. View Article : Google Scholar
|
|
9
|
Lee YT, Tan YJ and Oon CE: Molecular
targeted therapy: Treating cancer with specificity. Eur J
Pharmacol. 834:188–196. 2018. View Article : Google Scholar
|
|
10
|
Bianchini G, Balko JM, Mayer IA, Sanders
ME and Gianni L: Triple-negative breast cancer: Challenges and
opportunities of a heterogeneous disease. Nat Rev Clin Oncol.
13:674–690. 2016. View Article : Google Scholar :
|
|
11
|
Wein L, Luen SJ, Savas P, Salgado R and
Loi S: Checkpoint blockade in the treatment of breast cancer:
Current status and future directions. Br J Cancer. 119:4–11. 2018.
View Article : Google Scholar :
|
|
12
|
Lee A and Djamgoz MBA: Triple negative
breast cancer: Emerging therapeutic modalities and novel
combination therapies. Cancer Treat Rev. 62:110–122. 2018.
View Article : Google Scholar
|
|
13
|
Gahr S, Ocker M, Ganslmayer M, Zopf S,
Okamoto K, Hartl A, Leitner S, Hahn EG and Herold C: The
combination of the histone-deacetylase inhibitor trichostatin A and
gemcitabine induces inhibition of proliferation and increased
apoptosis in pancreatic carcinoma cells. Int J Oncol. 31:567–576.
2007.
|
|
14
|
Jang JH, Cho YC, Kim KH, Lee KS, Lee J,
Kim DE, Park JS, Jang BC, Kim S, Kwon TK and Park JW: BAI, a novel
Cdk inhibitor, enhances farnesyltransferase inhibitor
LB42708-mediated apoptosis in renal carcinoma cells through the
downregulation of Bcl-2 and c-FLIP (L). Int J Oncol. 45:1680–1690.
2014. View Article : Google Scholar
|
|
15
|
Wang XN, Wang KY, Zhang XS, Yang C and Li
XY: 4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human
breast cancer cells to adriamycin as a specific HDAC6 inhibitor by
promoting HIPK2/p53 pathway. Biochem Biophys Res Commun.
504:812–819. 2018. View Article : Google Scholar
|
|
16
|
Schopf FH, Biebl MM and Buchner J: The
HSP90 chaperone machinery. Nat Rev Mol Cell Boil. 18:345–360. 2017.
View Article : Google Scholar
|
|
17
|
Talaei S, Mellatyar H, Asadi A, Akbarzadeh
A, Sheervalilou R and Zarghami N: Spotlight on 17-AAG as an Hsp90
inhibitor for molecular targeted cancer treatment. Chem Biol Drug
Des. 93:760–786. 2019. View Article : Google Scholar
|
|
18
|
Kamal A, Thao L, Sensintaffar J, Zhang L,
Boehm MF, Fritz LC and Burrows FJ: A high-affinity conformation of
Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature.
425:407–410. 2003. View Article : Google Scholar
|
|
19
|
Mellatyar H, Talaei S,
Pilehvar-Soltanahmadi Y, Barzegar A, Akbarzadeh A, Shahabi A,
Barekati-Mowahed M and Zarghami N: Targeted cancer therapy through
17-DMAG as an Hsp90 inhibitor: Overview and current state of the
art. Biomed Pharmacother. 102:608–617. 2018. View Article : Google Scholar
|
|
20
|
Zagouri F, Sergentanis TN, Chrysikos D,
Papadimitriou CA, Dimopoulos MA and Psaltopoulou T: Hsp90
inhibitors in breast cancer: A systematic review. Breast.
22:569–578. 2013. View Article : Google Scholar
|
|
21
|
Pontes FSC, Pontes HAR, de Souza LL, de
Jesus AS, Joaquim AMC, Miyahara LAN, Fonseca FP and Pinto Junior
DS: Effect of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on
Akt protein expression is more effective in head and neck cancer
cell lineages that retain PTEN protein expression. J Oral Pathol
Med. 47:253–259. 2018. View Article : Google Scholar
|
|
22
|
Modi S, Stopeck A, Linden H, Solit D,
Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME,
Sugarman S, et al: HSP90 inhibition is effective in breast cancer:
A phase II trial of tanespimycin (17-AAG) plus trastuzumab in
patients with HER2-positive metastatic breast cancer progressing on
trastuzumab. Clin Cancer Res. 17:5132–5139. 2011. View Article : Google Scholar
|
|
23
|
Raja SM, Clubb RJ, Bhattacharyya M, Dimri
M, Cheng H, Pan W, Ortega-Cava C, Lakku-Reddi A, Naramura M, Band V
and Band H: A combination of Trastuzumab and 17-AAG induces
enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2
degradation and cytotoxicity in ErbB2-overexpressing breast cancer
cells. Cancer Boil Ther. 7:1630–1640. 2008. View Article : Google Scholar
|
|
24
|
Jensen MR, Schoepfer J, Radimerski T,
Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R,
Drysdale MJ, et al: NVP-AUY922: A small molecule HSP90 inhibitor
with potent antitumor activity in preclinical breast cancer models.
Breast Cancer Res. 10:R332008. View Article : Google Scholar :
|
|
25
|
Cheng Q, Chang JT, Geradts J, Neckers LM,
Haystead T, Spector NL and Lyerly HK: Amplification and high-level
expression of heat shock protein 90 marks aggressive phenotypes of
human epidermal growth factor receptor 2 negative breast cancer.
Breast Cancer Res. 14:R622012. View Article : Google Scholar :
|
|
26
|
Chelladurai P, Boucherat O, Stenmark K,
Kracht M, Seeger W, Bauer UM, Bonnet S and Pullamsetti SS:
Targeting histone acetylation in pulmonary hypertension and right
ventricular hypertrophy. Br J Pharmacol. Nov 20–2019.(Epub ahead of
print).
|
|
27
|
Mirzaei H, Ghorbani S, Khanizadeh S,
Namdari H, Faghihloo E and Akbari A: Histone deacetylases in
virus-associated cancers. Rev Med Virol. 30:e20852020. View Article : Google Scholar
|
|
28
|
Guo P, Chen W, Li H, Li M and Li L: The
histone acetylation modifications of breast cancer and their
therapeutic implications. Pathol Oncol Res. 24:807–813. 2018.
View Article : Google Scholar
|
|
29
|
Hassell KN: Histone deacetylases and their
inhibitors in cancer epigenetics. Diseases. 7:E572019. View Article : Google Scholar
|
|
30
|
Huang M, Huang J, Zheng Y and Sun Q:
Histone acetyltransferase inhibitors: An overview in synthesis,
structure-activity relationship and molecular mechanism. Eur J Med
Chem. 178:259–286. 2019. View Article : Google Scholar
|
|
31
|
Sanaei M and Kavoosi F: Histone
deacetylases and histone deacetylase inhibitors: Molecular
mechanisms of action in various cancers. Adv Biomed Res. 8:632019.
View Article : Google Scholar :
|
|
32
|
Falkenberg KJ and Johnstone RW: Histone
deacetylases and their inhibitors in cancer, neurological diseases
and immune disorders. Nat Rev Drug Discov. 13:673–691. 2014.
View Article : Google Scholar
|
|
33
|
Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee
KH, Kim TY, Han SW, Oh DY, Kim TY, et al: Histone deacetylase
inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances
anti-tumor effects of the poly (ADP-ribose) polymerase (PARP)
inhibitor olaparib in triple-negative breast cancer cells. Breast
Cancer Res. 17:332015. View Article : Google Scholar :
|
|
34
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View Article : Google Scholar
|
|
35
|
Tate CR, Rhodes LV, Segar HC, Driver JL,
Pounder FN, Burow ME and Collins-Burow BM: Targeting
triple-negative breast cancer cells with the histone deacetylase
inhibitor panobinostat. Breast cancer Res. 14:R792012. View Article : Google Scholar :
|
|
36
|
Aldana-Masangkay GI and Sakamoto KM: The
role of HDAC6 in cancer. J Biomed Biotechnol. 2011:8758242011.
View Article : Google Scholar
|
|
37
|
Boyault C, Sadoul K, Pabion M and Khochbin
S: HDAC6, at the crossroads between cytoskeleton and cell signaling
by acetylation and ubiquitination. Oncogene. 26:5468–5476. 2007.
View Article : Google Scholar
|
|
38
|
Krämer OH, Mahboobi S and Sellmer A:
Drugging the HDAC6-HSP90 interplay in malignant cells. Trends
Pharmacol Sci. 35:501–509. 2014. View Article : Google Scholar
|
|
39
|
Rao R, Fiskus W, Yang Y, Lee P, Joshi R,
Fernandez P, Mandawat A, Atadja P, Bradner JE and Bhalla K: HDAC6
inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone
function in human leukemia cells. Blood. 112:1886–1893. 2008.
View Article : Google Scholar
|
|
40
|
Plumb JA, Finn PW, Williams RJ, Bandara
MJ, Romero MR, Watkins CJ, La Thangue NB and Brown R:
Pharmacodynamic response and inhibition of growth of human tumor
xenografts by the novel histone deacetylase inhibitor PXD101. Mol
Cancer Ther. 2:721–728. 2003.
|
|
41
|
Qian X, LaRochelle WJ, Ara G, Wu F,
Petersen KD, Thougaard A, Sehested M, Lichenstein HS and Jeffers M:
Activity of PXD101, a histone deacetylase inhibitor, in preclinical
ovarian cancer studies. Mol Cancer Ther. 5:2086–2095. 2006.
View Article : Google Scholar
|
|
42
|
Paoluzzi L, Scotto L, Marchi E, Zain J,
Seshan VE and Connor OA: Romidepsin and belinostat synergize the
antineoplastic effect of bortezomib in mantle cell lymphoma. Clin
Cancer Res. 16:554–565. 2010. View Article : Google Scholar
|
|
43
|
Thomas A, Rajan A, Szabo E, Tomita Y,
Carter CA, Scepura B, Lopez-Chavez A, Lee MJ, Redon CE, Frosch A,
et al: A phase I/II trial of belinostat in combination with
cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial
tumors: A clinical and translational study. Clin Cancer Res.
20:5392–5402. 2014. View Article : Google Scholar :
|
|
44
|
Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG,
Yoo HJ and Lee SJ: The heat shock protein 90 inhibitor SNX5422 has
a synergistic activity with histone deacetylase inhibitors in
induction of death of anaplastic thyroid carcinoma cells.
Endocrine. 51:274–282. 2016. View Article : Google Scholar
|
|
45
|
Nguyen A, Su L, Campbell B, Poulin NM and
Nielsen TO: Synergism of heat shock protein 90 and histone
deacetylase inhibitors in synovial sarcoma. Sarcoma.
2009:7949012009. View Article : Google Scholar :
|
|
46
|
Zismanov V, Drucker L and Gottfried M: ER
homeostasis and motility of NSCLC cell lines can be therapeutically
targeted with combined Hsp90 and HDAC inhibitors. Pulm Pharmacol
Ther. 26:388–394. 2013. View Article : Google Scholar
|
|
47
|
Jamdade VS, Sethi N, Mundhe NA, Kumar P,
Lahkar M and Sinha N: Therapeutic targets of triple-negative breast
cancer: A review. Br J Pharmacol. 172:4228–4237. 2015. View Article : Google Scholar :
|
|
48
|
Conlin AK and Seidman AD: Taxanes in
breast cancer: An update. Curr Oncol Rep. 9:22–30. 2007. View Article : Google Scholar
|
|
49
|
Sikov WM, Berry DA, Perou CM, Singh B,
Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER,
et al: Impact of the addition of carboplatin and/or bevacizumab to
neoadjuvant once-per-week paclitaxel followed by dose-dense
doxorubicin and cyclophosphamide on pathologic complete response
rates in stage II to III triple-negative breast cancer: CALGB 40603
(Alliance). J Clin Oncol. 33:13–21. 2015. View Article : Google Scholar
|
|
50
|
von Minckwitz G, Schneeweiss A, Loibl S,
Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S,
Gerber B, et al: Neoadjuvant carboplatin in patients with
triple-negative and HER2-positive early breast cancer (GeparSixto;
GBG 66): A randomised phase 2 trial. Lancet Oncol. 15:747–756.
2014. View Article : Google Scholar
|
|
51
|
Zhan Y, Chen Y, Liu R, Zhang H and Zhang
Y: Potentiation of paclitaxel activity by curcumin in human breast
cancer cell by modulating apoptosis and inhibiting EGFR signaling.
Arch Pharm Res. 37:1086–1095. 2014. View Article : Google Scholar
|
|
52
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar
|
|
53
|
Ashton JC: Drug combination studies and
their synergy quantification using the Chou-Talalay method--letter.
Cancer Res. 75:24002015. View Article : Google Scholar
|
|
54
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
55
|
Kim D, Pertea G, Trapnell C, Pimentel H,
Kelley R and Salzberg SL: TopHat2: Accurate alignment of
transcriptomes in the presence of insertions, deletions and gene
fusions. Genome Biol. 14:R362013. View Article : Google Scholar :
|
|
56
|
Trapnell C, Roberts A, Goff L, Pertea G,
Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L:
Differential gene and transcript expression analysis of RNA-seq
experiments with TopHat and cufflinks. Nat Protoc. 7:562–578. 2012.
View Article : Google Scholar :
|
|
57
|
Trapnell C, Hendrickson DG, Sauvageau M,
Goff L, Rinn JL and Pachter L: Differential analysis of gene
regulation at transcript resolution with RNA-seq. Nat Biotechnol.
31:46–53. 2013. View Article : Google Scholar
|
|
58
|
Feng G, Du P, Krett NL, Tessel M, Rosen S,
Kibbe WA and Lin SM: A collection of bioconductor methods to
visualize gene-list annotations. BMC Res Notes. 3:102010.
View Article : Google Scholar :
|
|
59
|
Kovacs JJ, Murphy PJ, Gaillard S, Zhao X,
Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB and Yao TP: HDAC6
regulates Hsp90 acetylation and chaperone-dependent activation of
glucocorticoid receptor. Mol Cell. 18:601–607. 2005. View Article : Google Scholar
|
|
60
|
Chen D, Sun Y, Wei Y, Zhang P, Rezaeian
AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC and Ma L:
LIFR is a breast cancer metastasis suppressor upstream of the
Hippo-YAP pathway and a prognostic marker. Nat Med. 18:1511–1517.
2012. View Article : Google Scholar :
|
|
61
|
Wyckoff JB, Pinner SE, Gschmeissner S,
Condeelis JS and Sahai E: ROCK- and myosin-dependent matrix
deformation enables protease-independent tumor-cell invasion in
vivo. Curr Biol. 16:1515–1523. 2006. View Article : Google Scholar
|
|
62
|
Garmpis N, Damaskos C, Garmpi A,
Kalampokas E, Kalampokas T, Spartalis E, Daskalopoulou A, Valsami
S, Kontos M, Nonni A, et al: Histone deacetylases as new
therapeutic targets in triple-negative breast cancer: Progress and
promises. Cancer Genomics Proteomics. 14:299–313. 2017.
|
|
63
|
Park Y, Lee KS, Park SY, Kim JH, Kang EY,
Kim SW, Eom KY, Kim JS and Kim IA: Potential prognostic value of
histone deacetylase 6 and acetylated heat-shock protein 90 in
early-stage breast cancer. J Breast Cancer. 18:249–255. 2015.
View Article : Google Scholar :
|
|
64
|
Kekatpure VD, Dannenberg AJ and
Subbaramaiah K: HDAC6 modulates Hsp90 chaperone activity and
regulates activation of aryl hydrocarbon receptor signaling. J Biol
Chem. 284:7436–7445. 2009. View Article : Google Scholar :
|
|
65
|
Li D, Marchenko ND and Moll UM: SAHA shows
preferential cytotoxicity in mutant p53 cancer cells by
destabilizing mutant p53 through inhibition of the HDAC6-Hsp90
chaperone axis. Cell Death Differ. 18:1904–1913. 2011. View Article : Google Scholar :
|
|
66
|
Dietz KC and Casaccia P: HDAC inhibitors
and neurodegeneration: At the edge between protection and damage.
Pharmacol Res. 62:11–17. 2010. View Article : Google Scholar :
|
|
67
|
Dokmanovic M, Clarke C and Marks PA:
Histone deacetylase inhibitors: Overview and perspectives. Mol
Cancer Res. 5:981–989. 2007. View Article : Google Scholar
|
|
68
|
Marks PA, Richon VM and Rifkind RA:
Histone deacetylase inhibitors: Inducers of differentiation or
apoptosis of transformed cells. J Natl Cancer Inst. 92:1210–1216.
2000. View Article : Google Scholar
|
|
69
|
Kushner MH, Ory V, Graham GT, Sharif GM,
Kietzman WB, Thevissen S, Yuan M, Schmidt MO, Wellstein A and
Riegel AT: Loss of ANCO1 repression at AIB1/YAP targets drives
breast cancer progression. EMBO Rep. 21:e487412020. View Article : Google Scholar
|
|
70
|
Wang L, Wang C, Tao Z, Zhao L, Zhu Z, Wu
W, He Y, Chen H, Zheng B, Huang X, et al: Curcumin derivative WZ35
inhibits tumor cell growth via ROS-YAP-JNK signaling pathway in
breast cancer. J Exp Clin Cancer Res. 38:4602019. View Article : Google Scholar :
|
|
71
|
Chen W, Bai Y, Patel C and Geng F:
Autophagy promotes triple negative breast cancer metastasis via YAP
nuclear localization. Biochem Biophys Res Commun. 520:263–268.
2019. View Article : Google Scholar
|
|
72
|
Wang X, Su L and Ou Q: Yes-associated
protein promotes tumour development in luminal epithelial derived
breast cancer. Eur J Cancer. 48:1227–1234. 2012. View Article : Google Scholar
|
|
73
|
Overholtzer M, Zhang J, Smolen GA, Muir B,
Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA: Transforming
properties of YAP, a candidate oncogene on the chromosome 11q22
amplicon. Proc Natl Acad Sci USA. 103:12405–12410. 2006. View Article : Google Scholar
|
|
74
|
Liu X, Li H, Rajurkar M, Li Q, Cotton JL,
Ou J, Zhu LJ, Goel HL, Mercurio AM, Park JS, et al: Tead and AP1
coordinate transcription and motility. Cell Rep. 14:1169–1180.
2016. View Article : Google Scholar :
|
|
75
|
Gaggioli C, Hooper S, Hidalgo-Carcedo C,
Grosse R, Marshall JF, Harrington K and Sahai E: Fibroblast-led
collective invasion of carcinoma cells with differing roles for
RhoGTPases in leading and following cells. Nat Cell Biol.
9:1392–1400. 2007. View Article : Google Scholar
|
|
76
|
Schlienger S, Campbell S and Claing A:
ARF1 regulates the Rho/MLC pathway to control EGF-dependent breast
cancer cell invasion. Mol Biol Cell. 25:17–29. 2014. View Article : Google Scholar :
|
|
77
|
Zanconato F, Forcato M, Battilana G,
Azzolin L, Quaranta E, Bodega B, Rosato A, Bicciato S, Cordenonsi M
and Piccolo S: Genome-wide association between YAP/TAZ/TEAD and
AP-1 at enhancers drives oncogenic growth. Nat Cell Biol.
17:1218–1227. 2015. View Article : Google Scholar :
|
|
78
|
Lamar JM, Stern P, Liu H, Schindler JW,
Jiang ZG and Hynes RO: The Hippo pathway target, YAP, promotes
metastasis through its TEAD-interaction domain. Proc Natl Acad Sci
USA. 109:E2441–E2450. 2012. View Article : Google Scholar
|
|
79
|
Delve E, Co V, Regmi SC, Parreno J,
Schmidt TA and Kandel RA: YAP/TAZ regulates the expression of
proteoglycan 4 and tenascin C in superficial-zone chondrocytes. Eur
Cell Mater. 39:48–64. 2020. View Article : Google Scholar
|
|
80
|
Faião-Flores F, Emmons MF, Durante MA,
Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler
SS, Rix U, et al: HDAC inhibition enhances the in vivo efficacy of
MEK inhibitor therapy in uveal melanoma. Clin Cancer Res.
25:5686–5701. 2019. View Article : Google Scholar :
|
|
81
|
Han H, Yang B, Nakaoka HJ, Yang J, Zhao Y,
Le Nguyen K, Bishara AT, Mandalia TK and Wang W: Hippo signaling
dysfunction induces cancer cell addiction to YAP. Oncogene.
37:6414–6424. 2018. View Article : Google Scholar :
|
|
82
|
Liu Y, Xing H, Jiang X, Chen Y, Huang M
and Yu S: Network pharmacology-based preventive effect of XZF on
cutaneous toxicities induced by EGFR inhibitor. Biomed
Pharmacother. 123:1097552020. View Article : Google Scholar
|
|
83
|
Wang X, Li XD, Fu Z, Zhou Y, Huang X and
Jiang X: Long noncoding RNA LINC00473/miR1955p promotes glioma
progression via YAP1TEAD1Hippo signaling. Int J Oncol. 56:508–521.
2020.
|
|
84
|
Zucchini C, Manara MC, Cristalli C,
Carrabotta M, Greco S, Pinca RS, Ferrari C, Landuzzi L, Pasello M,
Lollini PL, et al: ROCK2 deprivation leads to the inhibition of
tumor growth and metastatic potential in osteosarcoma cells through
the modulation of YAP activity. J Exp Clin Cancer Res. 38:5032019.
View Article : Google Scholar :
|
|
85
|
Renda I, Bianchi S, Vezzosi V, Nori J,
Vanzi E, Tavella K and Susini T: Expression of FGD3 gene as
prognostic factor in young breast cancer patients. Sci Rep.
9:152042019. View Article : Google Scholar :
|
|
86
|
Shuai Y, Ma Z, Liu W, Yu T, Yan C, Jiang
H, Tian S, Xu T and Shu Y: TEAD4 modulated LncRNA MNX1-AS1
contributes to gastric cancer progression partly through
suppressing BTG2 and activating BCL2. Mol Cancer. 19:62020.
View Article : Google Scholar :
|
|
87
|
Wang J, Zou Y, Wu X, Chen M, Zhang S, Lu X
and Wang Q: DACH1 inhibits glioma invasion and tumor growth via the
Wnt/catenin pathway. Onco Targets Ther. 11:5853–5863. 2018.
View Article : Google Scholar :
|
